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New assessment of platelet deposition in small
caliber vascular prostheses using technetium-99m
apcitide scintigraphy in rabbit model
Tomomi Hasegawa, MD, PhD, Kenji Okada, MD, PhD, Yutaka Okita, MD, PhDINTRODUCTION
A high antithrombogenicity is one of essential factors
for the successful development of small caliber vascular
prostheses in peripheral or coronary artery bypass surgery.
There is therefore a demand for methodology that can
accurately evaluate platelet deposition in prosthetic vascular
grafts.
The platelet deposition is traditionally assessed with
Indium-111 (111In) platelet scintigraphy(1-3). This meth-
odology is considered to be a useful technique to detect
platelet deposition of the luminal surface of vascular grafts.
Thakur (4) conjectured that 111In-platelet scintigraphy has
a good sensitivity and specificity for the investigation of
platelet deposition because 111In-platelets are incorporated
directly into a growing thrombus. However, we recently
reported the efficacy and limitation of 111In-platelet scin-
tigraphy in the assessment of platelet deposition in vascular
prostheses (5). This technique has several drawbacks in-
cluding a harvesting of autologous platelets, a long radio-
pharmaceutical half-life and a limited sensitivity.
Technetium-99m (99mTc) apcitide is a diagnostic ra-
diopharmaceutical based upon a synthetic peptide that
preferentially binds to glycoprotein IIb/IIIa receptors
found on activated platelets. Although 99mTc-apcitide scin-
tigraphy has been recently used for the detection of acute
deep venous thrombosis(6-8), there has been no report of
its application to the assessment of platelet deposition in
vascular prostheses. The purpose of this study was to inves-
tigate the efficacy of 99mTc-apcitide scintigraphy in the
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840assessment of platelet deposition in small caliber vascular
prostheses, compared with 111In-platelet scintigraphy.
MATERIALS AND METHODS
Animal model
Thirty-six Japanese white rabbits weighting 2.5 to 3.5
kg were used for this study and divided into two groups by
the selection of platelet scintigraphy: 99mTc-apcitide scin-
tigraphy (Group I, 18 animals) or 111In-platelet scintigra-
phy (Group II, 18 animals). The handling of laboratory
animals and their use in experiments conformed to the
“Guidelines for Animal Experiment at Kobe University
Graduate School of Medicine” and “Guide for the Care
and Use of Laboratory Animals” published by the National
Academy Press(9).
Surgical procedure
Animals were anesthetized with an initial intravenous
dose of 20 mg/kg of pentobarbital sodium. Supplemental
doses were given when required. Additional local anesthe-
sia, containing 1% lidocaine, was applied in the cervical
portion. Using sterile technique, a midline cervical incision
was made and bilateral common carotid arteries were ex-
posed. Following systemic heparinization (100 IU/kg), the
grafts of 2cm lengthwere interposedbilaterally in each animal.
Anastomoses were performed in an end-to-end fashionwith 8
to10 stitches of interrupted sutures of 8-0 polypropylene.The
common carotid arteries were declamped and patency of all
grafts was evaluated by direct visualization before layered
surgical closure. Neither antiplatelet nor anticoagulant ther-
apy was administered after graft implantation. Totally, thirty-
six grafts were implanted and evaluated in each group.
Vascular prosthesis
Experimental 2-mm internal diameter grafts were
fibrin-coated knitted polyester vascular prostheses with
an elastic spinal outer reinforce. The grafts were coated
with fibrin glue as previously described(10). Briefly,
20mL of blood from normal human donors was col-
lected with 4mL of acid-citrate-dextrose (ACD) antico-
agulant solution. Plasma was extracted by centrifugation
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0.22 m filter for sterilization. After soaking the pros-
thetic graft in a solution containing 5000U of thrombin
(Mochida Pharmaceutical Co., Tokyo, Japan) and 10%
calcium chloride, the graft was clamped at one end and
plasma was injected under pressure with a syringe until
all pores were filled. Finally, the prosthesis was rinsed
with heparinized Hank’s buffer and air-dried at 25°C.
99mTc-apcitide scintigraphy
The 99mTc-apcitide was prepared from single-dose, ster-
ile, non-pyrogenic lyophilized kits (AcuTect; Berlex Labora-
tories, Inc,Wayne, NJ) in accordance with the package insert.
Briefly, each kit was formulated to contain 100g of the
peptide bibapcitide. To radiolabel the peptide with 99mTc,
each kit was reconstituted with 1 to 3 mL of sterile, nonpy-
rogenic, oxidant-free sodium 99mTc-pertechnetate in 0.9%
sodium chloride. The reconstituted kit was heated in a
boiling water bath for 15 minutes and then allowed to cool
before proceeding. At 1 hour before graft explantation,
animals were injected with a dose of approximately 100 g
of the peptide bibapcitide radiolabeled with 740 MBq of
99mTc intravenously.
111In-platelet scintigraphy
Autologous platelets were labeled with radioactive
111In-oxine as previously described(4). Briefly, 40mL of
autologous blood was collected with 6mL of ACD antico-
agulant solution through a catheter inserted in the ear
artery of awaken rabbits, followed by isolation of platelet
rich plasma by centrifugation (200G for 10minutes). Plate-
Fig 1. Graft region of interest (ROI) in semi-quantitative analy-
sis. By using the iSSPView image program, graft ROI (10 x 5
pixels) was traced on the scintigraphic image of vascular prosthesis
and the platelet activity of the graft ROI was measured.lets were pelletized by centrifugation (1000G for 10 min-utes) and suspended in normal saline/ACD solution. Then
platelets were incubated with 10 to 37 MBq of 111In-
oxyquinoline solution (Amersham international plc., UK)
for 10minutes at 37°C. After centrifugation (1000G for 10
minutes), the pellet was resuspended in 5mL of normal
saline/ACD solution and reinjected intravenously at 24
hours before graft explantation.
Graft explantation
The grafts were explanted at 1, 3, 7, 10, 14 and 30 days
after implantation (six grafts at each end point in each
group) under the same general anesthesia as that of graft
implantation. In graft explantation, patency of the grafts
was determined by palpation of pulses in the graft and distal
artery and heparin sodium (200IU/kg) was administrated
intravenously to prevent blood clotting. Explanted grafts
were immediately immersed and gently flushed with nor-
mal saline to remove any external blood. Animals were
euthanized by receiving a lethal dose of intravenous potas-
sium chloride.
Scintigraphic analysis
After graft explantation, radiolabeled platelets depos-
ited on the graft were counted for one minute immediately
by using a gamma well counter (1470 WIZARD; Wallac,
Turku, Finland) for a quantitative analysis. The number of
radiolabeled platelets was expressed as counts per minute
(cpm). Scintigraphic images were taken visually by using a
large field-of-view gamma camera (E-CAM; Toshiba,
Tokyo, Japan) equipped with a parallel-hole collimator.
Images were acquired for a minimum of 500000 counts per
view and stored in a 64  64 matrix. For a semi-quantita-
tive analysis, region of interest (ROI) analysis(11) was per-
Fig 2. Radiolabeled platelet deposition of graft in quantitative
analysis. Although there was no statistically significant difference in
time-dependent changes of radiolabeled platelet deposition be-
tween both groups, the radiolabeled platelet deposition in Group I
was significantly higher than that in Group II on each day after
graft implantation. *P0.001 vs. Group II.formed by using the iSSPView image program (version
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Briefly, graft ROI (10  5 pixels) was traced on the
scintigraphic image of vascular prosthesis (Figure 1) and
platelet activity of the graft ROI was measured and ex-
pressed as counts per pixel (cpp). Both visual and semi-
quantitative analyses were performed by two experienced
observers (Y.I. and H.K.) who were unaware of the data of
quantitative analysis.
Statistical analysis
All values are expressed as the means  standard devi-
ation (SD). After scintigraphic image and data analysis,
subsequent statistical analyses were performed with the
Statview (Version 5.0) software package (Abacus Concepts
Inc, Berkeley, CA). To evaluate the validity of 99mTc-
apcitide scintigraphy in the assessment of platelet deposi-
tion, time-dependent curves of platelet deposition or graft
ROI in both groups were compared by two-way analysis of
Fig 3. Scintigraphic images of the grafts in visual analy
(B) POD 7, (C) POD10. Bottom, Group II (111In-pla
Scintigraphic images in Group I were visualized earlier a
day.
Table I. Detection rate for platelet deposition in
scintigraphic images
Scintigraphy Positive(n) Negative(n) Detection rate(%)
Group I (99mTc) 36 0 100*
Group II (111In) 24 12 67
*P  0.001 vs. Group II.variance (ANOVA). Scintigraphic images were classified“positive” or “negative”, depending on whether or not it
was possible to detect the platelet deposition visually. The
differences between the two groups with regard to the
detection rate for platelet deposition in scintigraphic im-
ages were analyzed using the McNemar 2 test. Simple
linear regression analysis was performed by the least squares
method to determine the relationship between platelet
activity of graft ROI in semi-quantitative analysis and ra-
diolabeled platelet deposition of graft in quantitative anal-
ysis in each group. The linear regression line was set to start
at the origin (y intercept, zero) because of theoretical
hypothesis. P value of less than 0.05 was considered statis-
tically significant.
RESULTS
All grafts in both groups were patent without macro-
scopic stenosis and thrombus. Radiolabeled platelet depo-
sition of the grafts in quantitative analyses, which was
evaluated by using a gamma well counter, was shown in
Figure 2. In Group I and II, the radiolabeled platelet
deposition increased steeply after postoperative day (POD)
3 and reached a maximal level on POD 10. Afterward it
decreased gradually. Although the two-way ANOVA re-
vealed no significant difference in time-dependent changes
of radiolabeled platelet deposition between the two groups
(F1.7, P0.15), the radiolabeled platelet deposition in
op, Group I (99mTc-apcitide scintigraphy): (A) POD 1,
scintigraphy): (D) POD 1, (E) POD 7, (F) POD 10.
ore clearly than those in Group II. POD, postoperativesis. T
telet
nd mGroup I was significantly higher that that in Group II on
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on POD 7 and 14).
Visual analyses in both groups were shown in Figure 3.
Scintigraphic images in Group I were visualized earlier and
more clearly than those in Group II. In Group II, the
images on POD 1 and 3 were so indistinct that it was
difficult to trace them for graft ROIs (Figure 3-D). The
detection rate for platelet deposition in the present study
was 100% in Group I, whereas 67% in Group II (Table I).
Scintigraphy in Group I showed a significantly greater detec-
tion rate than that in Group II with McNemar 2 test
(P.001). Semi-quantitative analyses of scintigraphic images
were shown in Figure 4. Although the two-way ANOVA
revealed no significant difference in time-dependent changes
of platelet activity of graft ROI (F1.1, P.39), the plate-
let activity in Group I was significantly higher than that in
Group II on each POD (P.0001 on POD 1, 3 and 30,
P.0025 on POD7, P.0012 on POD10, P.0038 on
POD14). In each group, the simple regression analysis
revealed that platelet activity of graft ROI in semi-quanti-
tative analyses correlated significantly with radiolabeled
platelet deposition of graft in quantitative analysis
(P.0001, respectively), as shown in Figure 5.
DISCUSSION
[99mTcO] apcitide, the technetium complex of the 13
amino acid, apcitide, cyclo-(D-Tyr-Apc-Gly-Asp-Cys)-Gly-
Gly-Cys(Acm)-Gly-Cys(Acm)-Gly-Gly-Cys-NH2, where
Apc is L-[S-(3-aminopropyl)]cystein (an arginine mimetic)
and Acm is the acetamidomethyl protecting group, has
high affinity and selectivity for the GPIIb/IIIa receptor
that is expressed on the membrane surface of activated
platelets and plays an integral role in platelet aggregation
Fig 4. Platelet activity of graft ROI in semi-quantitative analysis.
Although there was no statistically significant difference in time-
dependent changes of platelet activity of graft ROI between both
groups, the platelet activity in Group I was significantly higher than
that in Group II on each day after graft implantation. *P.01 vs.
Group II. ROI, region of interest.and thrombus formation. Bibapcitide, a 26 amino acid,bis-succinimidomethyl ether-linked dimmer of the peptide
apcitide has been formulated as a single-vial, lyophilized kit
having the trade name AcuTect. When sterile, nonpyro-
genic sodium pertechnetate (99mTcO4
) in 0.9% sodium
chloride is added to AcuTect radiopharmaceutical kit and
the resulting kit is heated, [99mTcO] apcitide forms. This is
the first radiopharmaceutical to target acute deep vein
thrombosis (DVT) in the lower extremities(12). Patient
studies indicated that scintigraphy using [99mTcO] apcitide
is a safe and sensitive method for diagnosing acute DVT(8).
Scintigraphic techniques can be used to determine the
location and extent of the active (acute) thrombi and 99mTc
is the preferred radionuclide for diagnostic nuclear medi-
cine because of its ideal physical properties (6.02 h half-life,
140keV, r-emission), high purity, commercial availability
and low cost. Our primary concept in this study is to apply
AcuTect to the assessment of platelet deposition in small
Fig 5. Correlation between platelet activity of graft ROI in semi-
quantitative analysis and radiolabeled platelet deposition of graft in
quantitative analysis. (A) Group I, (B) Group II. There was a
significant correlation with high coefficient determination between
the platelet activity and the radiolabeled platelet deposition in each
group. ROI, region of interest.caliber vascular prostheses.
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let deposition in the field of small caliber vascular prostheses
is 111In-platelet scintigraphy. There are many studies of
acute thrombus, platelet deposition and antiplatelet medi-
cation with 111In-platelet scintigraphy in clinical and exper-
imental applications(1-3). We also studied platelet deposi-
tion of fibrin-coated small caliber vascular prostheses that
we used in the present study recently(5;13). However,
111In-platelet scintigraphy has several drawbacks as previ-
ously reported. First, the harvesting of autologous platelets
must need various processes before injection in an activated
state and the radiolabeling efficiency of harvested platelets
is affected by the processing condition(14). Secondly, the
relatively long radiopharmaceutical half-life of 111Indium
(2.8 days) precludes serial observations(15). Thirdly, 111In-
platelets have demonstrated slow blood clearance, resulting
in poor target-to-background ratios over the course of
several hours after injection(16). The need to delay evalua-
tion for 24 hours after injection of 111In-platelets hinders
rapid diagnosis of thrombosis(17). In addition, our recent
report (5) indicated some another limitations of 111In-
platelet scintigraphy including the limited sensitivity.
111In-platelet scintigraphy has low sensitivity for the inac-
tive (chronic) thrombus and small platelet deposition of less
than 1.2  104 cpm to acquire a good-quality of scinti-
graphic image.
The present study demonstrated that 99mTc-apcitide
can reliably evaluate platelet deposition in small caliber
vascular prostheses in a rabbit model. The platelet deposi-
tion, which was not detected macroscopically, was quanti-
fied accurately by 99mTc-apcitide scintigraphy. Between
99mTc-apcitide scintigraphy and 111In-platelet scintigra-
phy, there was no statistically significant difference in time-
dependent changes of radiolabeled platelet deposition in
quantitative analysis and platelet activity of graft ROI in
semi-quantitative analysis on small caliber vascular prosthe-
ses. In both scintigraphies, the platelet activity of graft ROI
was significantly correlated with the radiolabeled platelet
deposition with high coefficient determination. However,
99mTc-apcitide scintigraphy was able to visualize platelet
deposition earlier and more clearly than 111In-platelet scin-
tigraphy, and detection rate for platelet deposition in
99mTc-apcitide scintigraphy was significantly higher than
that in 111In-platelet scintigraphy. The radiolabeled plate-
let deposition and the platelet activity of graft ROI in
99mTc-apcitide scintigraphy was also significantly higher
than those in 111In-platelet scintigraphy. It was because
positive scintigraphic images are associated with a high
nuclear activity. 99mTc-apcitide scintigraphy has a higher
nuclear activity (740MBq) in accordance with the standard
protocol, compared with 111In-platelet scintigraphy (10 to
37MBq).Moreover, 99mTc-apcitide scintigraphy can iden-
tify all platelets both which are already deposited on the
luminal surface of graft andwhich are newly attached during 2
hours after the injection of 99mTc-apcitide, by binding to
these platelets.On the other hand, 111In-platelet scintigraphy
can only identify new platelets which are attached on the
luminal surface of graft during 24 hours after the injectionof 111In-platelets, and it can detect only 111In-platelet
deposition in the new platelet deposition visually. This
difference of the identification of platelet deposition be-
tween 99mTc-apcitide scintigraphy and 111In-platelet scin-
tigraphy can also explain the difference of their sensitivity in
visual analysis.
The preparation of 99mTc-apcitide was simple and
easy. It took approximately 30 minutes for the radiolabeled
preparation in 99mTc-apcitide scintigraphy in this study,
whereas 2 to 3 hours in 111In-platelet scintigraphy. The
major technical advantage in 99mTc-apcitide scintigraphy
was no need for harvesting and radiolabeling autologous
platelets. It gave great benefits of not only short preparation
time but also no invasion for animals and stable radiolabel-
ing efficiency. Moreover, 99mTc-apcitide scintigraphy can
take an early imaging of platelet deposition (10 to 60
minutes postinjection), which enable to detect acute
thrombosis immediately. The short radiopharmaceutical
half-life of 99mTechnetium has a potential to make serial
observations of platelet deposition. In addition to these
advantages, 99mTc-apcitide scintigraphic imaging provides
images of good quality with good sensitivity, which we
showed in this study. The above-mentioned characteristics
of 99mTc-apcitide scintigraphy are very useful to assess
platelet deposition in small caliber vascular prostheses, es-
pecially in a clinical situation. It is important to check the
graft status and the effect of antiplatelet medication after
cardiovascular surgery. We can get significant information
of the present platelet deposition on the implanted graft by
using 99mTc-apcitide scintigraphic imaging, and can re-
spond to the result quickly. The postoperatively accurate
evaluation and quick response for platelet deposition may
bring an improvement of graft patency. Although 111In-
platelet scintigraphy is not popularized clinically in the
assessment of small caliber vascular prostheses in the field of
cardiovascular surgery, we believe that 99mTc-apcitide scin-
tigraphy will become a standard methodology for the as-
sessment in the clinical setting.
The limitation of this study is that there were no
thrombotic events as graft stenosis and occlusion. Betes et
al. reported that 99mTc-apcitide scintigraphy can detect
new, actively forming thrombi as abnormal results whereas
old, inactive thrombi as normal results in the presence of
residual abnormalities (18), as same as 111In-platelet scin-
tigraphy. Further studies of 99mTc-apcitide scintigraphy
are still required to evaluate the pattern of platelet deposi-
tion in graft thrombosis.
In conclusion, 99mTc-apcitide scintigraphy is a new
diagnostic examination to evaluate platelet deposition in
small caliber vascular prostheses. This methodology has
more advantages including simple preparation, noninvasive
technique, early and accurate detection for platelet deposi-
tion and is superior to 111In-platelet scintigraphy. 99mTc-
apcitide scintigraphy has a potential utility in assessment of
platelet deposition in the field of cardiovascular surgery and
may be used as an alternative to 111In-platelet scintigraphy
in the detection of acute thrombosis.
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